The removal of the legacy lagged-pricing contract is a structural positive for future revenue quality, but the QoQ revenue decline and negative operating cash flow are near-term headwinds. Watch for FY27 guidance in late August and the closing of the Ewoyaa sale (~$71M) and first CGF convertible tranche (~$46M) in Q3 CY26 — these will clarify the cash runway and growth trajectory.
Price Chart
Executive Summary
Elevra Lithium reported Q4 FY26 (June 2026) operational results: spodumene concentrate production rose 15% QoQ to 54,479 dmt, but revenue fell 61% QoQ to $31M due to the finalization of a legacy lagged-pricing offtake contract. The company completed a $196M institutional placement and $102M convertible note facility to fully fund the NAL Brownfield Expansion, and agreed to sell its Ewoyaa Project interest for ~$71M cash. The quarter was operationally strong but financially transitional, with the legacy contract overhang removed and a fully funded growth pipeline in place.
Key Financial Metrics
Key Facts
- Spodumene concentrate production increased 15% QoQ to 54,479 dmt (second-best quarter on record).
- Lithium recovery improved to 71%, up 5% QoQ, with mill utilisation at 92%.
- Revenue fell 61% QoQ to $31M due to 39% lower tonnes sold and 37% lower average realized price ($921/dmt) from a legacy lagged-pricing contract.
- All legacy contract obligations have been satisfied; future pricing expected to align with spot spodumene prices.
- Completed $196M institutional placement and $102M convertible notes (Canada Growth Fund) to fully fund NAL Expansion.
- Agreed to sell Ewoyaa Project interest to Huayou for ~$71M cash, expected Q3 CY26.
- Cash balance ended at $255M (net cash $200M), up from $113M in March 2026.
- NAL reported $1M operating profit for the quarter; net operating cash outflow of $50M due to working capital movements.
- Guidance for FY27 to be provided with FY26 full-year results in late August.
Financial Impact
Revenue $31M (down 61% QoQ); cash $255M; NAL operating profit $1M; net operating cash outflow $50M; $196M equity + $102M convertible notes raised; $71M expected from Ewoyaa sale.
Risk Factors
- Spodumene spot price volatility could compress margins if prices decline from current levels.
- Execution risk on NAL Expansion staged ramp-up and cost control.
- Moblan permitting timeline remains the critical path for that project's FID.
- Convertible note issuance (Conditional Tranche ~$56M) requires future shareholder approval and may dilute equity.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3333949 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | Press Release | $24.90 | awaiting T+5 | — | $27.41 (+10.08%) |
Oct 22, 2026 5d ago | 6-K | $23.53 | awaiting T+5 | — | $27.41 (+16.49%) |
Oct 20, 2026 7d ago | Press Release | $26.94 $27.41 | ▲ +1.74% | ▲ +1.67% | $27.41 (+1.74%) |
Oct 16, 2026 11d ago | 6-K | $26.09 $24.90 | ▼ −4.56% | ▼ −4.42% | $27.41 (+5.06%) |
Oct 8, 2026 19d ago | 6-K | $33.61 $27.45 | ▼ −18.33% | ▼ −16.36% | $27.41 (−18.45%) |
Oct 1, 2026 26d ago | 6-K | $37.08 $33.61 | ▼ −9.36% | ▼ −10.52% | $27.41 (−26.08%) |
Oct 1, 2026 26d ago | Press Release | $37.08 $33.61 | ▼ −9.36% | ▼ −10.52% | $27.41 (−26.08%) |
Sep 30, 2026 27d ago | Press Release | $39.02 $34.71 | ▼ −11.05% | ▼ −12.96% | $27.41 (−29.75%) |
Aug 7, 2026 11w ago | Press Release | $60.34 $64.86 | ▲ +7.49% | ▲ +7.09% | $27.41 (−54.57%) |
Aug 4, 2026 12w ago | 6-K | $54.17 $59.69 | ▲ +10.19% | ▲ +10.29% | $27.41 (−49.40%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers